Verastem appoints Jonathan Pachter head of research
This article was originally published in Scrip
Verastem, a biopharmaceutical company developing cancer drugs, has appointed Dr Jonathan Pachter vice-president and head of research. Dr Pachter previously served as head of cancer biology at OSI Pharmaceuticals, where his team was responsible for the development of EMT (epithelial-mesenchymal transition) models to discover drugs that inhibit this process and the cancer stem cells that result.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.